Current Report Filing (8-k)
October 17 2016 - 6:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
October 7, 2016
ADVANCED
MEDICAL ISOTOPE CORP.
(Exact
name of Registrant as specified in its Charter)
Delaware
|
|
00-53497
|
|
80-0138937
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
No.)
|
|
(IRS
Employer
Identification
No.)
|
1021
N. Kellogg Street, Kennewick, WA 99336
(Address
of principal executive offices)
(509)
736-4000
(Registrant’s
Telephone Number)
Not
Applicable
(Former
name or address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Effective
October 7, 2016, Advanced Medical Isotope Corporation (the “
Company
”) filed a certificate of amendment to its
Certificate of Incorporation, a copy of which is attached hereto as Exhibit 3.1 (the “
Amendment
”), with the
Delaware Division of Corporations to effect a 1-for-100 reverse split of its authorized shares of Common Stock (the “
Reverse
Split
”). The Reverse Split will not impact the Company’s authorized shares of common stock, which currently remains
at 2.0 billion shares.
The
Reverse Split was approved by written consent of a majority of the Company’s shareholders on October 14, 2015. More information
on the Reverse Split can be found in the Company’s definitive information statement, filed with the Securities and Exchange
Commission on December 14, 2015, and mailed to each of the Company’s shareholders on or about the same date.
The
Reverse Split was announced by the Financial Industry Regulatory Authority (“
FINRA
”) on October 7, 2016, and
became effective on the OTC Pink Marketplace at the opening of trading on October 11, 2016 under the symbol “ADMDD”.
The “D” will appear on the Company’s ticker symbol for the next 20 business days. After 20 business days, the
Company’s common stock will resume trading under the symbol “ADMD”. The Company’s new CUSIP number is
00765X 201.
Item
9.01 Financial Statements and Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADVANCED
MEDICAL ISOTOPE CORP.
|
|
|
|
Date:
October 17, 2016
|
By:
|
/s/
James C. Katzaroff
|
|
|
James
C. Katzaroff
|
|
|
Chairman
and Chief Executive Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
|
|
|
3.1
|
|
Certificate
of Amendment to the Certificate of Incorporation of Advanced Medical Isotope Corporation, effective October 7, 2016
|
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vivos (QB) (USOTC:RDGL)
Historical Stock Chart
From Sep 2023 to Sep 2024